What is #geneediting? In our #CRISPRlingo series, we explain. Gene editing is a group of technologies that can be used to make changes to DNA for potential therapeutic benefit. #CRISPR/Cas9, for instance, is a type of #geneediting tool. Learn more: https://bit.ly/3LhSspB
Intellia Therapeutics, Inc.
生物技术研究
Cambridge,Massachusetts 57,663 位关注者
Developing curative genome editing treatments
关于我们
Intellia Therapeutics is a leading genome editing company whose mission is to develop potentially curative gene editing treatments that can positively transform the lives of people living with severe and life-threatening diseases. We are focused on the development of proprietary therapeutics using a recently developed biological tool known as the CRISPR/Cas9 system. The promise of the CRISPR/Cas9 system is the driving force behind the creation of Intellia. Our founders have a shared belief that the CRISPR/Cas9 technology has the potential to transform medicine by permanently editing disease-associated genes in the human body with a single treatment course. This technology offers the potential for us to develop curative therapeutic options for patients with chronic diseases by addressing the underlying cause of the disease. It can bring new hope and cures to people who now have nowhere to turn for help. Our combination of deep scientific expertise and clinical development experience, along with our leading intellectual property portfolio, puts Intellia in a unique position to unlock broad therapeutic applications of the CRISPR/Cas9 technology and create a new class of therapeutic products. Intellia has the right people, assets and ambitious vision needed to take full advantage of the CRISPR/Cas9 technology’s attributes – high potency, specificity, simplicity of use, broad applicability, and multifunctional programmability – and accelerate the advancement of curative products into the clinic. View our social media community guidelines at https://www.intelliatx.com/terms-and-conditions/ .
- 网站
-
https://www.intelliatx.com
Intellia Therapeutics, Inc.的外部链接
- 所属行业
- 生物技术研究
- 规模
- 501-1,000 人
- 总部
- Cambridge,Massachusetts
- 类型
- 上市公司
- 创立
- 2014
地点
-
主要
40 Erie Street
US,Massachusetts,Cambridge,02139
Intellia Therapeutics, Inc.员工
动态
-
$NTLA News: Intellia announces new date for its upcoming investor webcast to present data from the Phase 2 study of NTLA-2002 for the potential treatment of #hereditaryangioedema. https://lnkd.in/erhGSe3v
-
Yong Zhang, Ph.D., director of Allogeneic Cell Therapies, describes how thinking outside the box may lead to new possibilities in approaching #celltherapy #CRISPR #geneediting #GenomeJourney
-
Up next on our #CRISPRlingo series: Cas9. The Cas9 protein is a key component of the #CRISPR system that enables gene editing. At Intellia, we’re developing #CRISPR/Cas9-based therapies to help people living with a variety of conditions. Learn more: https://bit.ly/3LhSspB
-
$NTLA News: Intellia announced today the initiation of HAELO, a global, Phase 3 study of NTLA-2002, an investigational in vivo #CRISPR #geneediting treatment for #hereditary angioedema (#HAE). Full details here: https://lnkd.in/eszSVUDX
-
The annual meeting of the Oligonucleotide Therapeutics Society, scheduled for Oct. 6-9 in Montreal, Canada, will feature presentations from Intellia’s Vice President of Toxicology, Jonathan Phillips, Ph.D., and Director of Early Development, Rebecca Lescarbeau, PhD. More here: https://lnkd.in/gXsgtqD5 #CRISPR #geneediting #ots24
-
This week, Intellia will be at the HAE International (HAEi) Global Leaders Workshop/Global Angioedema Forum in Copenhagen, Denmark. HCPs: tune in to our presentations, sponsored symposium, or stop by our exhibit booth to learn more about #CRISPR #geneediting. ? www.intelliatx.com
-
$NTLA News: Data from the ongoing Phase 1 study of nexiguran ziclumeran (also known as NTLA-2001) for the potential treatment of #ATTR amyloidosis with cardiomyopathy will be presented in a late-breaking oral presentation at the 2024 American Heart Association (AHA) Scientific Sessions. The event will take place on Nov. 16 in Chicago, Illinois. More here: https://lnkd.in/e3eutETY #AHA24 #GeneEditing #CRISPR
-
Dr. Safi Shahda, senior medical director, Clinical Development, opens up about what makes working at Intellia so meaningful. #changelifestories #genomejourney
-
Meet Priya, an associate director in Ex Vivo Cell Therapy. Throughout her seven years at Intellia, she has built a strong network of colleagues in the industry and has taken advantage of the opportunities for continuous learning. www.intelliatx.com #CareerJourneys #OneIntellia